Johnson & Johnson (Pty) Ltd announced today it plans to split into two companies – separating its consumer health business, which is expected to generate $15bn in 2021 revenues, from its pharmaceutical and medical device businesses, which are expected to generate about $77bn in full-year revenues.
“For the new Johnson & Johnson, this planned separation underscores our focus on delivering industry-leading biopharmaceutical and medical device innovation and technology with the goal of bringing new solutions to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?